FORA Capital LLC Boosts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

FORA Capital LLC raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 121.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,180 shares of the company’s stock after acquiring an additional 9,958 shares during the quarter. FORA Capital LLC’s holdings in Dyne Therapeutics were worth $653,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Dyne Therapeutics by 47.7% during the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares in the last quarter. American International Group Inc. grew its holdings in shares of Dyne Therapeutics by 31.8% during the first quarter. American International Group Inc. now owns 29,138 shares of the company’s stock worth $827,000 after buying an additional 7,027 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after buying an additional 1,118,590 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Dyne Therapeutics by 29.9% during the first quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock worth $1,271,000 after buying an additional 10,317 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its holdings in shares of Dyne Therapeutics by 50.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the company’s stock worth $1,710,000 after buying an additional 20,000 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on DYN. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Guggenheim boosted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Stifel Nicolaus boosted their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $50.82.

Dyne Therapeutics Trading Up 6.5 %

DYN stock opened at $31.13 on Friday. Dyne Therapeutics, Inc. has a one year low of $10.12 and a one year high of $47.45. The firm has a market capitalization of $3.17 billion, a PE ratio of -8.74 and a beta of 1.10. The firm has a 50-day moving average of $31.89 and a two-hundred day moving average of $35.39.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Insider Activity

In other news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dirk Kersten sold 79,411 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now owns 234,127 shares in the company, valued at $8,533,929.15. This represents a 25.33 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 176,257 shares of company stock worth $6,193,718 in the last 90 days. Company insiders own 20.77% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.